https://www.selleckchem.com/pr....oducts/tecovirimat.h
Similar results were obtained for patients with low (1424) MII-2 levels compared with those with high (⩾1424) levels median PFS was 12.6 8.9 months (HR = 1.95, 95% CI 1.35-2.82, = 0.0004) and median OS was 32.4 14.6 months, respectively (HR = 2.42, 95% CI 1.64-3.57, 0.0001). Patients with low (6068) MII-3 levels had a longer median PFS and OS than those with high (⩾6068) levels 12.6 8.9 months (HR = 1.91, 95% CI 1.33-2.76, = 0.005) and 30.9 15.0 months (HR = 2.10, 95% CI 1.43-3.09, = 0.0002), respectively. Following
Like
Comment
Share
